PFE - Pfizer's Q2 Focus: Core Products And New Ventures
2024-07-25 15:30:25 ET
Summary
- Analysts predict Pfizer's Q2 2024 revenue to be around $13 billion?.
- The EPS estimate for Q2 2024 is $0.22, reflecting challenges from decreased COVID-19 product demand.
- Investors are closely watching the performance of Pfizer's core products, particularly in oncology and vaccines, excluding COVID-19 products.
- Significant focus is on how Pfizer manages upcoming patent expirations and the development of new drugs like Elrexfio for multiple myeloma?.
- PFE stock is a “hold” due to patent cliff risks and modest growth, suitable for value-oriented investors.
Pfizer's Second Act: Revamping Beyond COVID-19
My last article on Pfizer Inc. ( PFE ) saw the company just entering a recovery stage from the pandemic. Recall that Pfizer was one of two companies to pioneer an MRA vaccine for COVID-19. As the pandemic cooled off, COVID-related revenues dropped quickly and substantially, exposing the company to a lack of “core” growth. Noting this, I cautioned against adding (“hold”) and worried about their modest growth expectations and stock underperformance compared to the broader market. Since the article's publication in October, Pfizer's stock is off 10% compared to 27% gains from the S&P 500 (SP500)....
Pfizer's Q2 Focus: Core Products And New Ventures